Assuntos
Amish , Artrite/diagnóstico , Deficiências do Desenvolvimento/diagnóstico , Exantema/diagnóstico , Insuficiência de Crescimento/diagnóstico , Debilidade Muscular/diagnóstico , Artrite/complicações , Artrite/genética , Pré-Escolar , Deficiências do Desenvolvimento/complicações , Deficiências do Desenvolvimento/genética , Exantema/complicações , Exantema/genética , Insuficiência de Crescimento/complicações , Insuficiência de Crescimento/genética , Humanos , Masculino , Proteínas Monoméricas de Ligação ao GTP/genética , Debilidade Muscular/complicações , Debilidade Muscular/genética , Proteína 1 com Domínio SAM e Domínio HDRESUMO
Recent epidemiological studies established extremely rare incidence of Guillain-Barre syndrome (GBS) after contemporary H1N1-influenza vaccine. We saw five patients with 'atypical' GBS variants that started within four weeks of 2010/2011 H1N1-influenza vaccine. There was no evidence for other etiologies of GBS. The patients presented with sensory ataxia, areflexia, extremity and oropharyngeal paresthesias, numbness, pain, weakness, sphincteric disturbances, and dysautonomia. One patient had Miller Fisher syndrome. All had elevated cerebrospinal fluid protein, and classic electrodiagnostic finding suggestive of GBS. All received the treatment with intravenous immunoglobulin with variable response. These pilot observations suggest that H1N1-influenza vaccine may be associated with rare and atypical variants of GBS. However, epidemiological studies with large cohorts are necessary to confirm excess cases of atypical GBS after H1N1-influenza vaccination.
